Ultime notizie per Modular Medical (NASDAQ:MODD) Azioni

Modular Medical

Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

Modular Medical Inc

GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.67 by 46.27 percent. This is a 66.1 percent increase over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $303.316 million which beat the analyst consensus estimate of $279.570 million by 8.49 percent. This is a 70.24 percent increase over sales of $178.167 million the same period last year.

Earnings

Earnings Beats

News

GigaCloud Tech Q3 2024 GAAP EPS $0.98 Beats $0.67 Estimate, Sales $303.316M Beat $279.570M Estimate

WIIM

ACVA

ACV Auctions shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance.

Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) reported quarterly earnings of $0.47 per share which missed the analyst consensus estimate of $0.52 by 9.62 percent. The company reported quarterly sales of $112.771 million which missed the analyst consensus estimate of $112.933 million by 0.14 percent. This is a 6.86 percent increase over sales of $105.528 million the same period last year.

Earnings Misses

Karat Packaging Q3 2024 Adj. EPS $0.47 Misses $0.52 Estimate, Sales $112.771M Miss $112.933M Estimate

Ovintiv Q3 EPS $1.92

Income Opportunity Realty Q3 EPS $0.29 Down From $0.39 YoY

CARG

CarGurus shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 guidance and Q4 adjusted EPS guidance above estimates.

General

NVNI

Nvni Group Limited Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

EMX Royalty Q3 Sales $7.03M Down From $12.93M YoY

Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 13.64 percent decrease over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $165.00 thousand which beat the analyst consensus estimate of $80.00 thousand by 106.25 percent. This is a 17.02 percent increase over sales of $141.00 thousand the same period last year.

CRDF

Cardiff Oncology Q3 EPS $(0.25) Beats $(0.27) Estimate, Sales $165.00K Beat $80.00K Estimate

Biotech

ELTX

Elicio Therapeutics Shares ELI-002 Phase 1 Data At SITC 2024; Preliminary Results Show Dose-Dependent T Cell Responses Targeting KRAS Mutations And Link To Disease-Free Survival

Abacus Life (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.14 by 42.86 percent. The company reported quarterly sales of $28.148 million which missed the analyst consensus estimate of $28.461 million by 1.10 percent. This is a 33.27 percent increase over sales of $21.121 million the same period last year.

Abacus Life Q3 2024 Adj. EPS $0.20 Beats $0.14 Estimate, Sales $28.148M Miss $28.461M Estimate

EPRX

Eurpaxia Pharmaceuticals Q3 EPS $(0.17) Up From $(0.18) YoY

CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.17) by 141.18 percent. The company reported quarterly sales of $33.432 million which beat the analyst consensus estimate of $17.514 million by 90.88 percent. This is a 26.71 percent increase over sales of $26.384 million the same period last year.

CTMX

CytomX Therapeutics Q3 2024 GAAP EPS $0.07 Beats $(0.17) Estimate, Sales $33.432M Beat $17.514M Estimate

ALRM

Alarm.com shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 guidance.

Management

REZI

Resideo Unveils CEO Succession Plan As Jay Geldmacher Prepares To Retire In 2025; Vice-Chair Andrew C. Teich Named Next Chairman

Ever feel like the CBD market is on autopilot, stuck in a cycle of repetitive products and shrinking profit margins? For cannabis investors, this stuck-on-repeat dynamic has meant intense price pressure and dwindling returns.
Jaunty's CEO Nicolas Guarino knows a thing or two about survival. Before navigating the brutal CBD crash that slashed prices by 99%, he and his family weathered the economic and political upheaval of Chávez-era Venezuela. Now, in an industry dominated by dull uniformity, Guarino has led Jaunty to profitability by leaning into solventless products and creating an accessible, unpretentious brand.
Guarino's journey offers a fresh perspective and a profitable path forward for investors seeking stability in the face of volatility, proving that resilience is an asset that translates across borders and markets.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h2 class="wp-block-heading">Adiós  Chavez!</h2>
Guarino's roots are firmly planted in agriculture. He grew up working with water buffalo on family farms in southeastern <a href="https://www.benzinga.com/markets/cannabis/24/07/40068000/cannabis-legalization-in-venezuela-can-maduro-follow-colombias-lead-amid-political-upheaval-and-">Venezuela's </a>grassy savannah. Moving to New York for college, he brought with him the ethos of hard work and family ties. This background profoundly shaped his journey into the cannabis industry.
"Our family has always been about getting our hands dirty," Guarino told Benzinga Cannabis in an exclusive interview. "The values I learned back on the farm have been foundational in building Jaunty. It's about understanding the land, the crop, and the entire process, which, in turn, influences our approach to quality cannabis production."
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="768" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131239/IMG_1993-1024x768.jpeg" alt="" class="wp-image-633434" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131239/IMG_1993-1024x768.jpeg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131239/IMG_1993-300x225.jpeg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131239/IMG_1993-768x576.jpeg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131239/IMG_1993.jpeg 1440w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Courtesy of Jaunty</figcaption></figure>
<h2 class="wp-block-heading">CBD Market Carash And Escape From Commoditization</h2>
Entering the CBD space in 2017, Guarino and his team launched Jaunty as a producer and supplier of high-quality CBD oil for manufacturers across the U.S. However as the market became saturated, they quickly encountered the harsh realities of price compression. By 2020, Jaunty saw the<a href="https://www.benzinga.com/markets/cannabis/24/10/41147420/congressional-bill-is-game-changer-for-cbd-regulation-its-long-overdue-says-hemp-coalition"> price of CBD oil drop</a> to a meager $65 per kilo &#8211; a 99% decline from its peak, putting intense pressure on their wholesale business model.
&#8220;The CBD space became a game of scale,&#8221; Guarino explained. &#8220;The <a href="https://www.benzinga.com/markets/cannabis/24/10/41406637/top-5-cannabis-legalization-missteps-in-recent-u-s-history-a-selection">Farm Bill's structure</a> supports large-scale production but doesn't leave much room for smaller, quality-focused brands. We were nearly <a href="https://www.benzinga.com/markets/cannabis/24/10/41283230/epic-cannabis-fails-you-should-know-about-medmen-eaze-and-others-go-down-in-california-meltdowns">bankrupt,</a> but we couldn't quit. We saw an opening when New York moved towards recreational legalization.&#8221;
New York's decision to prioritize licenses for existing CBD operators was a lifeline. Guarino realized that to thrive in the THC market, Jaunty needed a brand that could stand apart, rather than relying on wholesale production alone. "It was clear we had to create a brand that would resonate on quality and effect," he said.
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/11/41780079/floridas-cannabis-initiative-defeated-trulieve-ceo-kim-rivers-nfls-ricky-williams-and-others-res"> Florida&#8217;s Cannabis Initiative Defeated: Trulieve CEO Kim Rivers, NFL&#8217;s Ricky Williams And Others Respond</a>
<h3 class="wp-block-heading">Building Jaunty: It's The Brand, Not Just The Product</h3>
When THC legalization got underway in New York, Guarino initially entertained deals with established brands like Old Pal, almost venturing into co-branding and white labeling. But he soon realized that these arrangements would pull Jaunty back into the commodity cycle he had just escaped.
"White labeling is for big facilities, with massive automation," he said. "We don't have that; we have exceptional extraction skills honed over years in <a href="https://www.benzinga.com/topic/hemp">CBD</a>. So, we decided to focus on <a href="https://www.benzinga.com/topic/cannabis-marketing">creating our brand rather than becoming just another supplier</a>."
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="819" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131331/Jaunty-Group-shot-with-all-9-carts-1024x819.jpg" alt="" class="wp-image-633437" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131331/Jaunty-Group-shot-with-all-9-carts-1024x819.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131331/Jaunty-Group-shot-with-all-9-carts-300x240.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131331/Jaunty-Group-shot-with-all-9-carts-768x614.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131331/Jaunty-Group-shot-with-all-9-carts.jpg 1350w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Courtesy of Jaunty</figcaption></figure>
This strategic decision led to the creation of Jaunty's product lines, starting with vapes and expanding to solventless Live Rosin Gummies. By prioritizing brand identity, Jaunty has been able to maintain a competitive edge in a market where differentiation is essential.
<h3 class="wp-block-heading">The Fam Behind The Brand</h3>
Jaunty's operations are more than just a business for Guarino, they are a family effort. He brought in his cousin from Venezuela who is a seasoned logistics expert, to run Jaunty's distribution. His cousin's experience managing 75 poultry trucks across Venezuela in challenging conditions was invaluable.
"With him overseeing our logistics, we are the only company in New York that guarantees delivery within 48 hours," Guarino said. "It's truly a blessing to have someone so experienced managing a crucial part of the business." This expertise has allowed Jaunty to achieve an impressively low 4.3% distribution cost relative to sales, enhancing profitability without sacrificing service quality.
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/11/41775784/hemp-vs-marijuana-industry-tensions-rise-amid-rejection-of-cannabis-legalization-in-florida-the-"> Hemp Vs. Marijuana: Industry Tensions Rise Amid Rejection Of Cannabis Legalization In Florida, The Dakotas</a>
<h3 class="wp-block-heading">A Few Cost-Effective Strategies</h3>
The decision to invest in butane <a href="https://www.benzinga.com/markets/cannabis/24/11/41760263/marijuana-growing-solution-provider-agrify-gets-20m-boost-from-green-thumb-to-power-up-cannabis-">extraction for specific products </a>reflects Jaunty&#8217;s calculated approach to innovation. &#8220;The full investment for our butane machine setup was around $500,000,&#8221; Guarino explained. &#8220;But with the right brand presence and strong distribution, we project a return on investment in four to five months."&nbsp;
Jaunty now places a strong emphasis on solventless products, reflecting an industry-wide shift towards purer, more natural cannabis experiences. According to Guarino, solventless extraction is a cost-effective method with high market appeal, particularly since it requires less investment compared to butane-based extraction.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131412/8-1024x683.jpg" alt="" class="wp-image-633438" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131412/8-1024x683.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131412/8-300x200.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131412/8-768x512.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131412/8-1536x1024.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131412/8.jpg 1620w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Courtesy of Jaunty</figcaption></figure>
"It's a lower capex approach that lets us offer high-quality products without the heavy initial investment," he said. In addition, by focusing on outdoor-grown cannabis, Jaunty has been able to keep costs low while achieving quality results comparable to indoor-grown products.
<h3 class="wp-block-heading">A Consumer-Centric Identity</h3>
Jaunty aims to create an accessible brand for cannabis users interested in oil-based products, especially those curious about moving from flower or nicotine vaping to cannabis oils.&nbsp;
Unlike many <a href="https://www.benzinga.com/topic/cannabis-branding">extract-focused brands</a>, which can feel exclusive or elitist, Jaunty's approach is deliberately welcoming. "Too many brands make consumers feel they aren't in the know. Jaunty is here to open up cannabis, not gatekeep it," Guarino said.
This inclusive identity is especially appealing to nicotine vapers exploring cannabis, with Jaunty offering an approachable entry point.&nbsp;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41764503/nebraska-says-yes-to-medical-cannabis-after-years-of-failed-legalization-attempts-heres-what-you">Nebraska Says Yes To Medical Cannabis After Years Of Failed Legalization Attempts: Here&#8217;s What You Need To Know</a>
<h3 class="wp-block-heading">&#8216;The Dab Crowd&#8217;</h3>
&#8220;Most extract-focused brands have a vibe like, ‘If you know, you know.' If you&#8217;re not part of the dab crowd, you're not cool enough," he added, highlighting how Jaunty takes the opposite approach by making cannabis feel approachable and not intimidating.
To help new users feel informed, Jaunty prioritizes consumer education, explaining oil types, effects, and product benefits in their packaging and interactions. "We take every opportunity to educate—about oil types, effects, and why you might choose one product over another," Guarino explained.
As they continue to grow, Jaunty is actively learning about its consumer base, even incorporating QR code surveys on packaging to gather direct feedback.&nbsp;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="807" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131438/Jaunty-Dreamberry-gummies-10-pack-creative-shot-color-pop-background-prop-with-fruit-1024x807.jpg" alt="" class="wp-image-633439" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131438/Jaunty-Dreamberry-gummies-10-pack-creative-shot-color-pop-background-prop-with-fruit-1024x807.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131438/Jaunty-Dreamberry-gummies-10-pack-creative-shot-color-pop-background-prop-with-fruit-300x236.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131438/Jaunty-Dreamberry-gummies-10-pack-creative-shot-color-pop-background-prop-with-fruit-768x605.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131438/Jaunty-Dreamberry-gummies-10-pack-creative-shot-color-pop-background-prop-with-fruit.jpg 1370w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Courtesy of Jaunty</figcaption></figure>
Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/10/41521360/8b-market-on-the-brink-texas-senator-calls-it-uncontrollable-proposes-erasing-hemp"> $8B Market On The Brink: Texas Senator Calls It &#8216;Uncontrollable,&#8217; Proposes Erasing Hemp</a>

Cannabis

Market Summary

Entrepreneurship

Retail Sales

Economics

Success Stories

Startups

Small Business

Exclusives

Markets

Tech

Interview

EXCLUSIVE: Surviving Chavez's Venezuela To CBD Crash - CEO Reveals How To Profit In A Market Stuck On Repeat

Tidewater shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 revenue below estimates.

American Realty Investors Q3 EPS Sales $11.607M Down From $12.526M YoY

Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.52 by 13.46 percent. The company reported quarterly sales of $404.530 million which beat the analyst consensus estimate of $400.423 million by 1.03 percent. This is a 2.21 percent increase over sales of $395.799 million the same period last year.

Pebblebrook Hotel Q3 2024 FFO $0.59 Beats $0.52 Estimate, Sales $404.530M Beat $400.423M Estimate

Fathom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHM#NASDAQ">FTHM</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.18) by 122.22 percent. The company reported quarterly sales of $83.733 million which missed the analyst consensus estimate of $91.804 million by 8.79 percent. This is a 10.47 percent decrease over sales of $93.524 million the same period last year.

FTHM

Fathom Holdings Q3 2024 GAAP EPS $(0.40) Misses $(0.18) Estimate, Sales $83.733M Miss $91.804M Estimate

Modular Medical drops 7%, prices $10M share offering

Modular Medical Inc (MODD) is down -3.20%% today. MODD has an Overall Score of 14. Find out what this means to you and get the rest of the rankings on MODD!See Full MODD ReportMODD stock closed at $1.25 and is down -$0.04 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as m

Should You Accumulate Modular Medical Inc (MODD) Stock Friday Morning?

Modular Medical (MODD) has released an update. Modular Medical, Inc. has struck a deal with Titan Partners Group for a firm commitment offering of ...

Modular Medical Secures $10M Deal with Titan Partners

The market has been high on Modular Medical Inc (MODD)  stock recently. MODD gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Modular Medical Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MODD!See Full MODD ReportWhat is Stock Sentiment?When

Is Modular Medical Inc (MODD) Stock About to Get Hot Friday?

Modular Medical, Gryphon Digital Mining to join Russell Microcap Index

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Modular Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/modd-stock-quote/">MODD</a>) just reported results for the fourth quarter of 2024.<ul><li>Modular Medical reported earnings per share of -14 cents. This was above the analyst estimate for EPS of -17 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/modd-stock-earnings-modular-medical-for-q4-of-2024/">MODD Stock Earnings: Modular Medical Beats EPS for Q4 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MODD Stock Earnings: Modular Medical Beats EPS for Q4 2024

Modular Medical initiates transfer of manufacturing operations to Phillips Medisize

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Modular Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/modd-stock-quote/">MODD</a>) just reported results for the first quarter of 2025.<ul><li>Modular Medical reported earnings per share of -12 cents. This was above the analyst estimate for EPS of -20 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/modd-stock-earnings-modular-medical-for-q1-of-2025/">MODD Stock Earnings: Modular Medical Beats EPS for Q1 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MODD Stock Earnings: Modular Medical Beats EPS for Q1 2025

Modular Medical (MODD) has provided an announcement. Modular Medical, Inc. introduced a Bonus Program to motivate its employees with stock options ...

Modular Medical Incentivizes FDA Milestones with Stock Options

Modular Medical reports issuance of U.S. patent covering key aspects of core pumping technology

GRYP

MODD

Press Releases

Modular Medical Announces FDA Clearance of the MODD1 Insulin Pump

Modular Medical Announces Conference Call to Discuss FDA Clearance of the MODD1 Insulin Pump

Growth Stocks Across Multiple Sectors-Innovators in Action: MODD, INBS, RCAT, KAVL, WHLR"

Modular Medical Announces Finalization of Protocol for GLP-1 Personalized Metabolic Therapy Study Utilizing the MODD1 Platform

Modular Medical Announces Issuance of U.S. Patent Covering Key Aspects of Core Pumping Technology

Events

Modular Medical to Present at the Lytham Partners Fall 2024 Investor Conference on October 1

Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX

New to The Street on Fox Business Premieres Exclusive Sponsored Programming Tonight Featuring Modular Medical (NASDAQ:MODD), Acurx Pharmaceuticals (NASDAQ:ACXP), and LightPath Technologies (NASDAQ:LPTH)

Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study

Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN

ACXP

CRDL

DBVT

INBS

KAVL

LPTH

NVDA

PRSO

RCAT

SGTM

SWISF

TSX:CRDL

VRAX

WHLR

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

HeartBeam

CytoSorbents

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Alpha Tau Medical

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Modular Medical

Notizie

Ultime notizie per Modular Medical (NASDAQ:MODD) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO